[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597479":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":34,"collaborators":10,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"ITAC (Instituto de Trasplantes y Alta Complejidad)","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"HSCT",null,"Adults with Allogeneic Hematopoietic Stem Cell Transplantation",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Maria Belen Rosales Ostriz, MD","CONTACT","+54 9 11 5047-6401","belenrosalesostriz@gmail.com",[19],{"facility":20,"status":21,"city":22,"state":10,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Instituto de Trasplantes de Alta Complejidad (ITAC)","RECRUITING","Buenos Aires","C1425EGH","Argentina","AR",{"type":27,"coordinates":28},"Point",[29,30],-58.37723,-34.61315,{"lat":30,"lon":29},[33],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":35,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100597479","thrombotic-microangiopathy-tma-associated-with-allogeneic-hematopoietic-stem-cell-transplantation-hsct-in-adult-patients-100597479",false,"NCT07059026","Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients","Prospective Study of Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients From Argentina","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) undergoing allogeneic HSCT in specialized centers that, as part of their usual follow-up protocol, carry out basic screening (laboratory\u002Fclinical) for TMA and in which patients consent (within the general transplant consent), to have their data used in observational studies.\n* Patients with ≥ 3\u002Flaboratory\u002Fclinical diagnostic markers of TMA in two consecutive assessments within 14 days, namely: 1-Elevated Schistocytes in peripheral blood; 2-LDH above the upper normal limit; 3-De novo thrombocytopenia or requirement for platelet transfusion; 4-De novo anemia or requirement for red blood cell transfusion; 5-High blood pressure (≥140\u002F90); 6-Protein\u002Fcreatinine ratio \\> 1mg\u002Fmg or proteinuria ≥ 30mg\u002Fdl in a random sample).\n* Patients with suspected\u002Fdiagnosed TMA who have signed the specific consent for the study.\n\nExclusion Criteria:\n\n* Participation in an interventional treatment study of any therapy for TMA.","ALL","18 Years",{"count":46,"type":47},200,"ESTIMATED","12 Months","OBSERVATIONAL","Thrombotic Microangiopathy (TMA) Associated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a serious complication that is associated with increased morbidity, related to multiple organ failure, with increased mortality in transplant patients. The incidence and evolution of TMA, especially in the adult population, is unclear due to the lack of early systematic screening and clear criteria for its diagnosis. For this reason, we designed this protocol to study the incidence and evolution of TMA Associated with allogeneic HSCT in adult patients from Argentina.",[52],"Thrombotic Microangiopathy",[54,55],"Thromobotic microangiopathy","Allogeneic Hematopoietic Stem Cell Transplantation","2025-07-09",{"date":58,"type":59},"2025-07-14","ACTUAL",{"date":61,"type":59},"2024-12-03",{"date":63,"type":47},"2027-12",{"name":5,"class":6},1]